

Junshi Biosciences Toripalimab' s Latest Clinical Data on Lung Cancer will Make its First Debut at WCLC

Junshi Biosciences announces today that the research data of its domestically developed anti-PD-1 mAb toripalimab in combination with chemotherapy in EGFR+ advanced NSCLC patients failed prior EGFR-TKI therapies will be released via oral presentation in World Conference on Lung Cancer (WCLC). **This will be the first debut for Junshi Biosciences toripalimab' s research findings in lung cancer research.**

2019 WCLC hosted by the International Association for the Study of Lung Cancer (IASLC) will be held from Sep.7th to Sep.10th 2019 in Barcelona, Spain.

The latest results of toripalimab in combination with chemotherapy in EGFR+ advanced NSCLC patients failed prior EGFR-TKI therapies (NCT03513666), which was led by Prof. Zhou Caicun of Shanghai Pulmonary Hospital, will be released via oral presentation in this WCLC. The specific release form and time are as follows:

Release Title: A PII study of toripalimab, a PD-1 mAb, in combination with chemotherapy in EGFR+ advanced NSCLC patients failed to prior EGFR TKI therapies

News Release



Release Form: Mini Oral

Release Time: 14:35~14:40 Sep.9th 2019(Local Time)

Release Place: Hilton Head (1978)

This is a prospective, multicenter, open-label, single-arm, phase II trial evaluating the efficacy and safety of toripalimab in combination with chemotherapy in EGFR+ advanced NSCLC patients who have failed prior EGFR-TKI therapies.

In the study, patients received toripalimab + pemetrexed/carboplatin for 4-6 cycles, followed by toripalimab + pemetrexed maintenance therapy until disease progression or intolerable toxicity. Tumor assessment was performed every 6 weeks. The primary endpoint was ORR at week 12 assessed by the investigators per RECIST version 1.1. The secondary endpoints were ORR, DOR, DCR, TTR, PFS, OS assessed by the investigators per RECIST version 1.1 and safety.

The results showed that the combination of toripalimab plus pemetrexed/carboplatin in EGFR+ advanced NSCLC patients who failed prior EGFR-TKI therapies had a promising antitumor efficacy with a tolerable safety profile.

Official Website: www.junshipharma.com

News Release



Should you have any questions, please contact:

厉智 | Zhi Li

E-mail: zhi_li@junshipharma.com

Corporate Communications Dept.